Pfizer’s Blockbuster Xeljanz & Other JAK Inhibitors More Dangerous Than Assumed—Heightened Warnings

Pfizer’s Blockbuster Xeljanz & Other JAK Inhibitors More Dangerous Than Assumed—Heightened Warnings

With a sizeable post-marketing safety study review complete, the U.S. Food and Drug Administration (FDA) concludes that risks for significant heart-related events, from myocardial infarction and stroke to greater risks for cancer, clotting, and even death, suggest considerable forthcoming changes in labels for tofacitinib, marketing as Xeljanz and Xeljanz XR, a drug type known as JAK Inhibitors.

TrialSite provides a brief summary breakdown for the community.

What’s the drug’s background?

JAK inhibitor commercialization is the result of a partnership between the National Institutes of Health and Pfizer. As opposed to a biologic, a small molecule drug interferes with the JAK-STAT signaling pathway, which is transmitting extracellular information into the cell nucleus and thus influencing DNA transcription. 

Who is the drug’s developer?

Pfizer

What are annual revenues?

Pfizer generated approximately $2.4 billion from this drug in 2020, bringing it into Blockbuster status.

What is the drug used for?

The drug is used primarily for rheumatoid arthritis, as well as psoriatic arthritis and ulcerative colitis.

What are common side effects?

Di...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee